Open-Label Pharmacokinetic Trial of Aldesleukin (rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects with Metastatic Renal Cell Carcinoma or Metastatic Melanoma with Immunologic Correlative Studies.

Trial Profile

Open-Label Pharmacokinetic Trial of Aldesleukin (rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects with Metastatic Renal Cell Carcinoma or Metastatic Melanoma with Immunologic Correlative Studies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Apr 2012

At a glance

  • Drugs Aldesleukin (Primary)
  • Indications Malignant melanoma; Renal cell carcinoma
  • Focus Pharmacokinetics
  • Sponsors Novartis; Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 27 Apr 2012 Company (Novartis Pharmaceuticals Corporation) added in associations field as reported by ClinicalTrials.gov.
    • 05 Apr 2011 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 05 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top